Purdue Pharma L.P. v. PAR Pharmaceutical, Inc.
1:13-cv-03374
Overview
Parties
Counter Claimant
Counter Defendant
The P.F. Laboratories, Inc. Operating Company
Represented By
3 Attorneys ListedGrunenthal GMBH NPE (Individual / Inventor)
Represented By
3 Attorneys ListedPurdue Pharmaceuticals L.P. NPE (University / Research)
Represented By
3 Attorneys ListedPurdue Pharma L.P. NPE (University / Research)
Represented By
3 Attorneys ListedCourt & Judges
Court
District Court, S.D. New York (nysd)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 22 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | US 8,114,383 Asserted | Asserted Patent | View Official Patent → |
| 🇺🇸 United States | US 8,075,872 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2007004822 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,192,722 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,420,056 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 8,309,060 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2012025163 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2013017107 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2014017007 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2014010583 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2016002258 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 2016007438 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 9,629,807 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 10,130,591 B2 | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US 10,058,548 B2 | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8114383
Abuse-proofed dosage form
|
Filed: 2003-11-20
Issued: 2012-02-14
|
Expired (Term Ended)
+325d PTA
Expires: 2024-10-10
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
High PTA (+325 days) / Cellect Scrutiny — Over 325 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
2
Dispositive
0
Granted
0
Denied
0
Pending / Review
2
Motions by Category
Key Dispositive Motions & Rulings